南非医护人员接种Ad26.COV2.S疫苗的有效性(Sisonke研究):单臂、开放标签、3B期实施研究结果
Sisonke研究为单臂、开放标签、3B期实施研究,2021年2月17日至5月17日入组并接种477102名医护人员,单剂5×10^10病毒颗粒Ad26.COV2.S疫苗,匹配215813名接种者与215813名未接种者。截至2021年7月17日,疫苗预防COVID-19相关死亡的有效性为83%(95%CI 75-89),预防需重症监护住院的有效性为75%(95%CI 69-82),预防住院的有效性为67%(95%CI 62-71),在beta与delta变异株流行期间保持一致。
要点
- 单剂Ad26.COV2.S疫苗预防COVID-19相关死亡有效性83%(95%CI 75-89)。
- 预防需重症监护住院有效性75%(95%CI 69-82),预防住院67%(95%CI 62-71)。
- beta与delta变异株流行期间疫苗有效性保持一致。
核心结论
- 单剂Ad26.COV2.S疫苗对重症COVID-19和COVID-19相关死亡显示有效性,对beta和delta变异株均有效,为全球使用提供真实世界证据。
研究设计与样本
- 单臂、开放标签、3B期实施研究(Sisonke研究),在南非122个接种点招募18岁及以上医护人员。
- 2021年2月17日至5月17日入组并接种477102名医护人员,其中女性357401名(74.9%)、男性119701名(25.1%),中位年龄42.0岁(33.0-51.0)。
- 参与者接种单剂5×10^10病毒颗粒的Ad26.COV2.S疫苗,接种者与两种国家医疗保险计划(计划A和计划B)的个人水平数据链接,并与普通人群中未接种者按COVID-19风险匹配。
- 215813名接种者与215813名未接种者匹配,主要结局为接种或匹配后28天及以上至数据截止时,医护人员相较普通人群的重症COVID-19疫苗有效性。
主要发现
- 截至2021年7月17日数据截止,总匹配队列中疫苗预防COVID-19相关死亡的有效性为83%(95%CI 75-89)。
- 预防需重症监护住院的COVID-19相关住院有效性为75%(95%CI 69-82),预防COVID-19相关住院有效性为67%(95%CI 62-71)。
- 三种结局的疫苗有效性在计划A和计划B中一致,在老年医护人员及包括HIV感染在内的合并症人群中维持。
- beta流行期间计划A加B预防COVID-19相关住院的有效性为62%(95%CI 42-76),delta流行期间为67%(95%CI 62-71)。
- beta流行期间预防COVID-19相关死亡的有效性为86%(95%CI 57-100),delta流行期间为82%(95%CI 74-89)。
关键数值与推荐
- 重症COVID-19定义为COVID-19相关入院、需重症或 intensive care 的住院或死亡。
- 疫苗有效性评估时间为接种或匹配后28天及以上至数据截止。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to assess the effectiveness of a single dose of the Ad26.COV2.S vaccine (Johnson & Johnson) in health-care workers in South Africa during two waves of the South African COVID-19 epidemic. METHODS: In the single-arm, open-label, phase 3B implementation Sisonke study, health-care workers aged 18 years and older were invited for vaccination at one of 122 vaccination sites nationally. Participants received a single dose of 5 × 1010 viral particles of the Ad26.COV2.S vaccine. Vaccinated participants were linked with their person-level data from one of two national medical insurance schemes (scheme A and scheme B) and matched for COVID-19 risk with an unvaccinated member of the general population. The primary outcome was vaccine effectiveness against severe COVID-19, defined as COVID-19-related admission to hospital, hospitalisation requiring critical or intensive care, or death, in health-care workers compared with the general population, ascertained 28 days or more after vaccination or matching, up to data cutoff. This study is registered with the South African National Clinical Trial Registry, DOH-27-022021-6844, ClinicalTrials.gov, NCT04838795, and the Pan African Clinical Trials Registry, PACTR202102855526180, and is closed to accrual. FINDINGS: Between Feb 17 and May 17, 2021, 477 102 health-care workers were enrolled and vaccinated, of whom 357 401 (74·9%) were female and 119 701 (25·1%) were male, with a median age of 42·0 years (33·0-51·0). 215 813 vaccinated individuals were matched with 215 813 unvaccinated individuals. As of data cutoff (July 17, 2021), vaccine effectiveness derived from the total matched cohort was 83% (95% CI 75-89) to prevent COVID-19-related deaths, 75% (69-82) to prevent COVID-19-related hospital admissions requiring critical or intensive care, and 67% (62-71) to prevent COVID-19-related hospitalisations. The vaccine effectiveness for all three outcomes were consistent across scheme A and scheme B. The vaccine effectiveness was maintained in older health-care workers and those with comorbidities including HIV infection. During the course of the study, the beta (B.1.351) and then the delta (B.1.617.2) SARS-CoV-2 variants of concerns were dominant, and vaccine effectiveness remained consistent (for scheme A plus B vaccine effectiveness against COVID-19-related hospital admission during beta wave was 62% [95% CI 42-76] and during delta wave was 67% [62-71], and vaccine effectiveness against COVID-19-related death during beta wave was 86% [57-100] and during delta wave was 82% [74-89]). INTERPRETATION: The single-dose Ad26.COV2.S vaccine shows effectiveness against severe COVID-19 disease and COVID-19-related death after vaccination, and against both beta and delta variants, providing real-world evidence for its use globally. FUNDING: National Treasury of South Africa, the National Department of Health, Solidarity Response Fund NPC, The Michael & Susan Dell Foundation, The Elma Vaccines and Immunization Foundation, and the Bill & Melinda Gates Foundation.
引用
- Bekker LG, Garrett N, Goga A, et al. Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. Lancet. 2022. PMID: 35305740. doi:10.1016/S0140-6736(22)00007-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。